Biogen Inc.
Location
Massachusetts
Founded
1978-02-28
Website
Risk Signals
2646 news mentions monitored
Industry Context
This company is tracked across risk categories, including those related to its sector (e.g., Pharmaceutical Preparations, Biological Products, Except Diagnostic Substances, Commercial Physical and Biological Research), including supply chain integrity, ESG practices, labor disputes, and regulatory compliance.
Filter risk signals by topic
Select a theme below to explore the company’s news mentions in specific risk areas.
Recent Articles about Biogen Inc.
Live alerts from global media, monitored by Business Radar
2025-01-31 (mmm-online.com)
Rx Rundown: Merck, Biogen, Pfizer and more - MM+M - Medical Marketing and Media
Check out this week’s medical marketing news, dealmaking and industry chatter.
Read more
2025-01-28 (saludnews.net)
Sage rejects biogen purchase offer and seeks strategic alternatives | News health
Biogen, which currently has 10.2% participation in Sage, had proposed to buy the remaining shares at a price of $ 7.22 per share. Sage Therapeutics has rejected an acquisition offer by biogen valued at 469 million dollars, arguing that the proposal "significantly underestimate" the value of the company and not ...
Read more
2025-01-24 (mmm-online.com)
Rx Rundown: AbbVie, Purdue Pharma, HHS and more - MM+M - Medical Marketing and Media
Check out this week’s medical marketing news, dealmaking and industry chatter.
Read more
2025-01-15 (biospace.com)
Dispatches From JPM, Biogen’s Sage Buyout Offer, Pfizer’s Obesity Play, More -
J&J, GSK, Eli Lilly and others struck high-value transactions in the early days of biopharma’s annual kickoff conference. Meanwhile, Biogen proposes to acquire struggling neuro partner Sage, and obesity dominates discussions as Pfizer goes “all in.”
Read more
2025-01-08 (marketbeat.com)
Farmers Trust Co. Acquires New Position in Biogen Inc. (NASDAQ:BIIB)
Farmers Trust Co. purchased a new position in Biogen Inc. (NASDAQ:BIIB - Free Report) in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 12,849 shares of the biotechnology company's stock, valued at approximately $1,965,000.
Read more
2024-12-17 (marketbeat.com)
Franklin Resources Inc. Sells 13,723 Shares of Biogen Inc. (NASDAQ:BIIB)
Franklin Resources Inc. cut its stake in shares of Biogen Inc. (NASDAQ:BIIB - Free Report) by 3.5% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 374,747 shares of the biotechnology company's stock after selling 13,723 shares during the period. Frankli
Read more
2024-12-03 (marketbeat.com)
BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp Sells 3,549 Shares of Biogen Inc. (NASDAQ:BIIB)
BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp lessened its position in shares of Biogen Inc. (NASDAQ:BIIB - Free Report) by 12.7% in the third quarter, according to its most recent filing with the SEC. The firm owned 24,289 shares of the biotechnology company's stock after selling 3,549 shares during
Read more
2024-12-01 (marketbeat.com)
zurcher kantonalbank zurich cantonalbank sells 3707 shares of biogen inc nasdaqbiib
Zurcher Kantonalbank Zurich Cantonalbank cut its stake in shares of Biogen Inc. (NASDAQ:BIIB - Free Report) by 5.1% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 69,649 shares of the biotechnology company's stock after
Read more
2024-10-06 (marketbeat.com)
Truist Financial Corp Sells 2,753 Shares of Biogen Inc. (NASDAQ:BIIB)
Truist Financial Corp lessened its holdings in shares of Biogen Inc. (NASDAQ:BIIB - Free Report) by 6.5% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 39,669 shares of the biotechnology company's stock after selling 2,
Read more